双特异性单链抗体BiTE在肿瘤靶向治疗中的研究进展  

Recent advances in bispecific single-chain antibodies BiTE in cancer targeted therapy

作　　者：董琼娜[1] 蒋华[1] 李宗海[1] 

机构地区：[1]上海交通大学医学院附属仁济医院,上海市肿瘤研究所癌基因及相关基因国家重点实验室,上海200032

出　　处：《中国科技论文》2012年第12期963-966,共4页China Sciencepaper

基　　金：高等学校博士学科点专项科研基金资助项目(20090073120109);十二五重大新药创制国家科技重大专项资助项目(2012ZX09103-301-005);上海市科委生物医药重点科技攻关项目(10431903700)

摘　　要：BiTE(bispecificTcellengager)是一种以T细胞作为效应细胞的双特异性单链抗体,它具有2个抗原结合部位,可以同时结合T细胞及病变细胞表面的抗原分子,从而有效地激活静止的T细胞,达到杀伤病变细胞的目的。其分子量小,易穿透肿瘤组织,缺乏Fc段,免疫源性低,是一种极具发展潜力的新型抗体形式。对BiTE的发展历程、结构和作用机制以及在肿瘤靶向治疗中的应用做简要综述。BiTE （bispecific T cell engager） is a bispecific single-chain antibody. By binding one of its arms to a specific cancer antigen and the other arm to a CD3 subunit ofT-cell receptors, BITE can efficiently activate resting T cells, achieving the aim of killing targeted cells. Compared to other bispeeific antibodies, BiTE is a novel and promising format due to its small molecule weight, easiness to infiltrate into cancer cells, lack of a fragment crystallizable （Fc） region and low immunogenicity. This review describes the development history of BiTE as well as its structme, mechanism and clinical application in cancer targeted therapy.

关 键 词：双特异性抗体 BITE 定向杀伤 肿瘤靶向治疗 

分 类 号：R730.5[医药卫生—肿瘤]